Immediate Impact

4 from Science/Nature 54 standout
Sub-graph 1 of 21

Citing Papers

Pancreatic cancer
2025 Standout
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
2024 Standout
7 intermediate papers

Works of Suman Redhu being referenced

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
2015
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
2014

Author Peers

Author Last Decade Papers Cites
Suman Redhu 649 463 620 10 1.1k
Vesna Šneller 578 573 357 12 982
Angel H. Bair 544 684 425 17 995
J. W. Chapman 449 174 904 15 1.4k
Ion Cotarla 367 323 534 19 1.0k
A. Shaw 372 762 612 17 1.1k
Yongchang Shi 566 436 530 9 1.3k
Lynda Grinsted 690 712 831 19 1.4k
Jakub Żołnierek 602 762 425 23 1.1k
Heidi Steinfeldt 687 393 580 10 1.1k
Tatyana A. Grushko 659 261 650 22 1.3k

All Works

Loading papers...

Rankless by CCL
2026